Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1876MR)

This product GTTS-WQ1876MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1876MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14877MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ7436MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ13861MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ15042MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ10595MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ5738MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ9586MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ3490MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BA1126
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW